NR1H4 and metabolic disease: The inhibition of intestinal FXR reduces the expression of various ceramide synthases to lower intestinal and blood ceramide levels, and the inhibition of ceramide biosynthesis as a lipotoxic inducer of metabolic disorders ameliorates a variety of metabolic diseases [101].